Ubs Group Ag Pharma Cyte Biotech, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PMCB
# of Institutions
30Shares Held
932KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$336,9180.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$309,7430.0% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$270,8020.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$148,2607.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$133,1900.17% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $33.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...